Activity Levels Vary Greatly Across Patients, With Effects Far From Clear
Children and teenagers with hemophilia are considerably more physically active than adult patients, possibly reflecting more recent emphasis on the…
Articles by Diana Campelo Delgado
Fitusiran Dosing in Trials Reduced to Lower Blood-clot Risk
Sanofi has reduced the dosing of its investigational treatment fitusiran in clinical trials to lower the risk of blood…
Kovaltry Safe, Effective for Children With Hemophilia A in Real-world Study
Kovaltry (octocog alfa) is effective and safe as a preventive treatment for children with…
Rixubis Seen as Safe, Effective for Hemophilia B in Real-world Study
Rixubis safely and effectively prevents and manages bleeding in children and adults with hemophilia B, a real-world study from South…
First Patient Dosed in Phase 3 Trial Testing Marstacimab, Pfizer’s TFPI Therapy
The first participant was dosed with the investigational therapy marstacimab in a Phase 3 clinical trial — still…
Enrollment Underway in Phase 4 Trial of Ixinity in Hemophilia B Patients Under Age 12
A Phase 4 trial investigating Ixinity as a prophylactic treatment for children under age 12 with hemophilia B has reached…